---
title: "BioCryst Raises Price of Key ORLADEYO Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272075639.md"
description: "BioCryst Pharmaceuticals has announced a price increase for its hereditary angioedema treatment, ORLADEYO, effective January 9, 2026. The U.S. wholesale acquisition cost will rise from $44,484.33 to $48,487.92 per 28-day pack. This increase may impact payers and patient access. Analysts currently rate BCRX stock as a Buy with a $30.00 price target, although TipRanks’ AI Analyst suggests a Neutral outlook due to mixed financial performance and strategic challenges. BioCryst focuses on developing oral therapies for rare diseases and has a market cap of $1.67 billion."
datetime: "2026-01-09T12:30:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272075639.md)
  - [en](https://longbridge.com/en/news/272075639.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272075639.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/272075639.md) | [繁體中文](https://longbridge.com/zh-HK/news/272075639.md)


# BioCryst Raises Price of Key ORLADEYO Treatment

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

BioCryst ( (BCRX) ) has issued an update.

Effective January 9, 2026, BioCryst Pharmaceuticals raised the U.S. wholesale acquisition cost of its hereditary angioedema treatment ORLADEYO (berotralstat) from $44,484.33 to $48,487.92 per 28-day pack, covering both the 150 mg and 110 mg capsule strengths, marking a notable price increase for one of the company’s key rare-disease products and with potential implications for payers and patient access.

The most recent analyst rating on (BCRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

**Spark’s Take on BCRX Stock**

According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.

BioCryst’s overall stock score reflects a mix of strong strategic moves and significant financial challenges. The positive impact of recent corporate events and earnings call guidance is offset by weak financial performance and valuation metrics. The company’s ability to address financial risks and capitalize on strategic initiatives will be crucial for future performance.

To see Spark’s full report on BCRX stock, click here.

**More about BioCryst**

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing oral therapies, including ORLADEYO (berotralstat), for rare diseases in the United States market.

**Average Trading Volume:** 5,084,399

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $1.67B

### Related Stocks

- [BioCryst Pharmaceuticals, Inc. (BCRX.US)](https://longbridge.com/en/quote/BCRX.US.md)

## Related News & Research

- [BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News](https://longbridge.com/en/news/281630381.md)
- [Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)](https://longbridge.com/en/news/281554239.md)
- [BullFrog AI Signs Major AI Drug Discovery Partnership](https://longbridge.com/en/news/281092205.md)
- [Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call](https://longbridge.com/en/news/281187029.md)
- [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/en/news/281323250.md)